Hormonal
Increased abundance of specific Firmicutes taxa (e.g., Ruminococcus gnavus, Lachnospiraceae) and Proteobacteria (e.g., Escherichia, Enterobacteriaceae) in obesity contributes to chronic low-grade inflammation and metabolic endotoxemia via LPS production and mucin degradation.
Obesity is linked to an increase in bacteria that produce lipopolysaccharides (LPS), which can leak into the bloodstream and cause chronic inflammation. This inflammation is fueled by a diet low in fiber and high in saturated fats. Prioritize fiber-rich foods (vegetables, legumes, whole grains) to support bacteria that maintain gut barrier integrity and reduce inflammation.
Furthermore, the relative abundance of several bacterial taxa belonging to Enterobacteriaceae family, known to exhibit endotoxic activity, was increased in the OB group... Escherichia and Escherichia albertii... represent an important source of LPS, which can affect the intestinal permeability leading to an increased concentration of LPS in plasma (endotoxemia), connected with the chronic low-grade inflammation typical of obese subjects
Why this rating
Strong observational correlation with clinical markers of inflammation and metabolic syndrome; functional prediction (PICRUSt) supports pathway analysis.
Source
Gut microbiota markers associated with obesity and overweight in Italian adults
Vanessa Palmas et al. · Scientific Reports · 2021
DOI 10.1038/s41598-021-84928-w
More from this paper
- Obesity and overweight are associated with a gut microbiota profile characterized by a significantly higher Firmicutes-to-Bacteroidetes ratio, increased abundance of SCFA-producing Firmicutes taxa (e.g., Lachnospiraceae, Ruminococcus gnavus), and decreased abundance of Bacteroidetes taxa (e.g., Bacteroides uniformis, Flavobacteriaceae).Good
- Higher adherence to the Mediterranean Diet (MD) and higher levels of physical activity are associated with a gut microbiota profile richer in Bacteroidetes (e.g., Flavobacterium, Pedobacter) and lower in Firmicutes, which correlates with lower body fat and higher muscle mass.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →